Episode 21 - New HIV Prevention: “What I’m Excited About” with Dr Raphael Landovitz

Going anti-Viral

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Raphael Landovitz from the UCLA Medical School about the latest information on HIV prevention via Preexposure Prophylaxis, or PrEP. They discuss the history of PrEP and early efficacy and then move into a discussion of the evolution of PrEP from episodic dosing to longer-acting therapies. The episode also highlights recent research and how that may impact the future of PrEP dosing.

0:00 - Introduction

1:59 - History of Preexposure Prophylaxis, or PrEP

5:39 - Why initial PrEP regimens were not 100% effective

12:01 - Discussion of episodic PrEP and 2-1-1 regimens

16:22 - How longer-acting therapy has been shown to be superior to episodic dosing

20:29 - LEVI syndrome - what is it?

25:05 - What the future holds for PrEP

29:18 - Closing Remarks

__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email [e-mail] to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
X
Facebook
Instagram
...